Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.
Cannabis Law Report
NOVEMBER 16, 2021
As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JANUARY 5, 2022
3 MyMD believes that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 according to a major investment bank. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.
Cannabis Law Report
DECEMBER 23, 2021
billion by 2025. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol. Global surveys of cannabis users indicate that around 40% of users have some medical component to their usage.
SMPL
MAY 26, 2020
CBD industry will be worth $16 billion by 2025. Perhaps the most critical turning point for CBD came in August 2013, when a CNN special hosted by Dr. Sanjay Gupta profiled a 6-year-old girl in Colorado, Charlotte Figi, who used CBD to treat her epilepsy, as well as the brawny brothers who grew her CBD, the Stanleys.
Cannabis Law Report
JULY 15, 2022
Last week, federal Health Minister Greg Hunt announced changes to regulations that would allow for medicinal cannabis exports, capitalising on what the Government estimated would be a $70 billion industry by 2025. So without going on to the advertising side of things, very important to have your clinical trials obviously based on products.
Puff Puff Post
DECEMBER 28, 2018
This is on par with the cost currently seen for those afflicted with ADHD and diabetes, with predictions for the cost to skyrocket further by 2025. Initially, he refused their requests due to insufficient data, however the evidence shown by a recent study done in Israel on CBD managing epilepsy was enough to sway him in the other direction.
Expert insights. Personalized for you.
52 
Let's personalize your content